N. Davie

发表

Prostacyclin Analogues Differentially Inhibit Growth of Distal and Proximal Human Pulmonary Artery Smooth Muscle Cells

M. Yacoub, J. Polak, N. Morrell, 2000, Circulation.

The science of endothelin‐1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies

N. Weissmann, F. Grimminger, R. Schermuly, 2009, European journal of clinical investigation.

Adrenomedullin expression and growth inhibitory effects in distinct pulmonary artery smooth muscle cell subpopulations.

M. Yacoub, D. Smith, J. Polak, 2001, American journal of respiratory cell and molecular biology.

Role of the adventitia in pulmonary vascular remodeling.

M. Frid, K. Stenmark, M. Das, 2006, Physiology.

Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.

M. Humbert, H. Ghofrani, A. Keogh, 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)

H. Ghofrani, F. Grimminger, G. Simonneau, 2014, European Respiratory Journal.

Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension

B. Dahal, W. Seeger, R. Brandes, 2011, Respiratory research.

Therapeutic efficacy of TBC 3711 in monocrotaline-induced pulmonary hypertension

B. Dahal, W. Seeger, R. Brandes, 2011 .

Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells.

G. Taylor, N. Morrell, J. Wharton, 2002, American journal of respiratory cell and molecular biology.

Pulmonary artery adventitial fibroblasts cooperate with vasa vasorum endothelial cells to regulate vasa vasorum neovascularization: a process mediated by hypoxia and endothelin-1.

K. Stenmark, E. Gerasimovskaya, P. Jones, 2006, The American journal of pathology.

Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells.

M. Frid, K. Stenmark, D. Hyde, 2004, American journal of physiology. Lung cellular and molecular physiology.

Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment

N. Klein, S. Hall, S. Haworth, 2011, European Respiratory Journal.

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells.

M. Yacoub, J. Polak, N. Morrell, 2002, American journal of respiratory and critical care medicine.

Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage.

M. Frid, K. Stenmark, N. Van Rooijen, 2006, The American journal of pathology.

pulmonary hypertension in chronically hypoxic rats Metalloproteinase inhibition by Batimastat attenuates

J. Tanus-Santos, D. Souza-Costa, M. Frid, 2006 .

Heterogeneity in Hypoxia-Induced Pulmonary Artery Smooth Muscle Cell Proliferation

M. Frid, K. Stenmark, N. Davie, 2004 .

Expression and function of angiotensin converting enzyme, chymase, and angiotensin II in the human radial artery and internal thoracic artery.

M. Amrani, M. Yacoub, J. Wharton, 2000, The Annals of thoracic surgery.

Differential adrenomedullin release and endothelin receptor expression in distinct subpopulations of human airway smooth-muscle cells.

D. Smith, N. Morrell, J. Wharton, 2001, American journal of respiratory cell and molecular biology.

Pulmonary Circulation and Hypoxia Hypoxia , leukocytes , and the pulmonary circulation

M. Frid, K. Stenmark, J. Reeves, 2004 .

A Potential Regulator of Vasa Vasorum Neovascularization in Hypoxia-Induced Pulmonary Vascular Remodeling*

K. Stenmark, Shama Ahmad, C. White, 2015 .

Extracellular adenosine triphosphate: a potential regulator of vasa vasorum neovascularization in hypoxia-induced pulmonary vascular remodeling.

K. Stenmark, Shama Ahmad, C. White, 2005, Chest.

Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study.

H. Ghofrani, G. Simonneau, M. Wilkins, 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)

M. Humbert, Z. Jing, H. Ghofrani, 2015, European Respiratory Journal.

Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice.

D. Webb, G. Alexander, A. Davenport, 2012, Life sciences.

Late-breaking abstract: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension

M. Humbert, Z. Jing, H. Ghofrani, 2014 .

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells.

M. Yacoub, J. Polak, N. Morrell, 2002, American journal of respiratory and critical care medicine.

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension

A. Torbicki, H. Ghofrani, F. Grimminger, 2016, Heart.

Effects of Multikinase inhibitors on pressure overload-induced right ventricular remodelling

B. Dahal, W. Seeger, S. Pullamsetti, 2013, Journal of Inflammation.

Circulating mononuclear cells with a dual, macrophage-fibroblast phenotype contribute robustly to hypoxia-induced pulmonary adventitial remodeling.

M. Frid, K. Stenmark, T. Carpenter, 2005, Chest.

Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA)

H. Ghofrani, W. Klepetko, M. Madani, 2014 .

Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.

M. Humbert, Z. Jing, H. Ghofrani, 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Comparison of hemodynamic parameters in treatment-naive and pretreated patients with pulmonary arterial hypertension (PAH) in the Phase III PATENT-1 study

M. Humbert, Z. Jing, H. Ghofrani, 2013 .

Comparison of hemodynamic parameters in patients with inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST-1 study

H. Ghofrani, G. Simonneau, M. Wilkins, 2013 .

Correlation of improvements in hemodynamics and exercise capacity in patients with PAH: Results from the phase III PATENT-1 study

M. Humbert, Z. Jing, H. Ghofrani, 2013 .

The science of endothelin‐1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies

N. Weissmann, F. Grimminger, R. Schermuly, 2009, European journal of clinical investigation.

Late-breaking abstract: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension

F. Grimminger, G. Simonneau, M. Wilkins, 2014 .